PD-L1 is expressed in PDACs, and its overexpression is associated with a poor prognosis.5 Preclinical investigations have shown that blocking PD-L1 inhibits pancreatic cancer development in animal models, suggesting that the PD-1/PD-L1 pathway could be a potential therapeutic target against PDAC.6 However, clinical trials have shown that targeting the PD-1/PD-L1 pathway with a single agent has only a modest effect in patients with PDAC,7–10 suggesting that in addition to PD-L1 expression, other targets for the treatment of PDAC must be identified. Here, CD274 is linked to familial pancreatic carcinoma.